Close Menu

NEW YORK (GenomeWeb) – Meridian Bioscience issued preliminary fiscal year 2017 earnings before the opening of the market today, reporting a 2 percent year-over-year increase in revenues.

Meridian expects revenues of $200.5 million for its fiscal year ending Sept. 30, 2017, including fourth quarter revenues of $49.5 million. Non-GAAP earnings per share should be in the $.66 to $.67 range for the year, according to the firm.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A Harvard-led team reprogrammed DNA methylation patterns of mice with eye problems to restore their sight, AFP reports.

A man in India is suing the Serum Institute of India, saying that he suffered serious side effects from a vaccine it is testing, but the institute has rejected those claims, the Economic Times reports.

The New York Times reports Moderna is planning a clinical trial of its SARS-CoV-2 vaccine in children.

In Nature this week: Readfish tool for targeted nanopore sequencing, genomic diversity of barley and wheat, and more.